Physician

Phu Ngoc Tran, M.D.

According to 2025 Medicare claims, Phu Tran, M.D. (NPI: 1891089587) practices hematology/oncology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is HEM ONC ASSOCIATES OF THE TREASURE COAST, PA (NPI: 1205882867; TIN: 650696665) and primary practice location at 34986-3414.

Tran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,176 traditional Medicare patients, billed 260,606 HCPCS/CPT codes, and received $3,830,277 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,752 prescription claims across 470 beneficiaries totaling $7,199,048 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 26 claims. Open Payments data shows 191 records totaling $7,745. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,479 to $3,830,277. Similarly, Part D prescription costs have moved sharply higher in recent years, from $7,638 to $7,199,048. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $5,167 to $1,299.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	22	330	$1,479
2017	182	347	$28,390
2018	344	1,361	$88,950
2019	418	1,774	$111,168
2020	804	49,014	$714,107
2021	1,125	192,029	$2,035,493
2022	980	199,125	$2,367,649
2023	994	163,683	$2,687,594
2024	1,176	260,606	$3,830,277

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	103	149	$7,638
2016	108	195	$4,708
2017	122	294	$49,493
2018	237	1,317	$847,701
2019	300	1,912	$1,564,554
2020	316	1,522	$968,802
2021	326	1,204	$1,011,943
2022	377	1,653	$2,956,534
2023	363	1,829	$3,738,109
2024	470	2,752	$7,199,048

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	171	$22,836
2019	N/R	97	$12,856
2020	N/R	114	$11,412
2021	N/R	68	$6,509
2022	N/R	26	$1,564
2023	N/R	56	$5,735
2024	N/R	26	$442

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	376	827	$69
82728	Ferritin (blood protein) level	315	639	$13
36415	Insertion of needle into vein for collection of blood sample	625	1,614	$9
80048	Blood test, basic group of blood chemicals (calcium, total)	275	601	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	747	2,302	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	83	2,156	$1,135,028
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	52	1,364	$709,752
Revlimid	Lenalidomide	37	1,015	$673,905
Xtandi	Enzalutamide	38	1,140	$539,277
Calquence	Acalabrutinib Maleate	24	720	$359,412

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$279
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	191	$7,745	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Phu Ngoc Tran, M.D.?

Tedicare shows public-source Medicare data for Phu Ngoc Tran, M.D. (NPI 1891089587), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Phu Ngoc Tran, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Phu Ngoc Tran, M.D.?

Phu Ngoc Tran, M.D. is linked to HEM ONC ASSOCIATES OF THE TREASURE COAST, PA (billing NPI 1205882867) in the available physician profile data.

Does Phu Ngoc Tran, M.D. have Open Payments data?

Phu Ngoc Tran, M.D. has 191 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.